Working... Menu

Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03546907
Recruitment Status : Active, not recruiting
First Posted : June 5, 2018
Last Update Posted : June 6, 2019
Regeneron Pharmaceuticals
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2019
  Estimated Study Completion Date : February 19, 2020